Pipeline
Therapies that Target the INNATE IMMUNE Response
| DN-TNF Platform | Disease Field | Pre-clinical | Phase I | Phase II (POC) | Pivotal | Est. Next Milestone |
|---|---|---|---|---|---|---|
Mild Alzheimer’s Disease CNS
XPRO™ |
Mild AD | P2 Start Q4-2021 | ||||
|
MCI
XPRO™ |
Mild Cognitive Impairment | P2 Start 1H-2022 | ||||
|
Treatment Resistant Depression
XPRO™ |
Treatment Resistant Depression |
P2 Start 1H-2022 |
INB03 for treatment of MUC4 positive cancer and LIVNate for NASH Phase II trials begin after resolution of pandemic
| NK-Priming Platform | Disease Field | Pre-clinical | Phase I | Phase II (POC) | Pivotal | Est. Next Milestone |
|---|---|---|---|---|---|---|
Inmune Bio for High-Risk MDS
INKmune™ |
Myelodysplastic Syndrome ONCOLOGY |
P1 Underway | ||||
Inmune Bio for High-Risk MDS
INKmune™ |
Ovarian Cancer | P1 Start 1H - 2022 |
INKmune for treatment of ovarian cancer Phase I trial begins after resolutions of pandemic